e.p.t.q. S300 Lidocaine by JETEMA Co., Ltd. is a dermal filler formulated with highly purified, cross-linked hyaluronic acid at a concentration of 24 mg/ml. The product is manufactured using the proprietary HIVE™ cross-linking technology, which is designed to support uniform gel distribution, controlled viscoelasticity, and reliable tissue integration.
Due to its medium density and balanced rheological properties, e.p.t.q. S300 Lidocaine is suitable for contouring and volumising applications in selected facial areas. The formulation allows for controlled shaping while maintaining flexibility and natural facial dynamics.
The product contains lidocaine to improve patient comfort during injection. e.p.t.q. S300 Lidocaine is supplied sterile, ready to use, and intended exclusively for administration by qualified healthcare professionals in an appropriate clinical environment.
When used by trained medical professionals, e.p.t.q. S300 Lidocaine is intended to:
- support medium-depth contour correction
- assist in restoring facial volume and definition
- contribute to smoother skin appearance
- maintain natural facial mobility
Typical areas of application include:
- lips
- nasolabial folds
- marionette lines
- cheeks
- nasal contouring (non-surgical)
- glabellar region (frown lines)
The duration and outcome of treatment may vary depending on individual anatomy, injection technique, and lifestyle factors.
Each package of e.p.t.q. S300 Lidocaine contains:
- Hyaluronic Acid – 24 mg/g
Highly purified, cross-linked hyaluronic acid (HIVE™ technology).
- Lidocaine – 0.3%
Included to improve comfort during the injection procedure.
- Package contents:
1 sterile pre-filled syringe with 1.1 ml of product.
Important Notice:
e.p.t.q. S300 Lidocaine is a CE-certified medical device intended for professional use only.
Administration must be carried out exclusively by qualified healthcare professionals.
This product information is provided for informational purposes only and does not replace medical advice or professional training.
Indications, contraindications, and treatment suitability must be assessed by the treating practitioner in accordance with the official instructions for use.